Gut Dysbiosis and Fecal Calprotectin Predict Response to Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma

Francesca Romana Ponziani, Angela De Luca, Anna Picca, Emanuele Marzetti, Valentina Petito, Federica Del Chierico, Sofia Reddel, Francesco Paroni Sterbini, Maurizio Sanguinetti, Lorenza Putignani, Antonio Gasbarrini, Maurizio Pompili – 8 March 2022 – The gut microbiota is a well‐known prognostic factor and a modulator of treatment sensitivity in patients with cancers treated with immune checkpoint inhibitors. However, data on hepatocellular carcinoma (HCC) are lacking.

Subscribe to